Program Description
In 2019, roughly 37,000 individuals received a new diagnosis of HIV in the United States. It is critical for antiretroviral therapy (ART) to be initiated as soon as possible after diagnosis, and measures should be taken for proper direction in care including a medication history, physical examination, laboratory evaluation, recording of specific markers, and drug-resistance testing. Pharmacists play an essential role in initiation of treatment and can assist with optimizing adherence, obtaining access to ART, and maintaining engagement. ART may also need to be modified depending on other conditions or concerns, such as blood glucose, pregnancy, metabolic issues, food insecurity, and co-infection with hepatitis B. Pharmacists are in a unique position as medication experts to provide guidance to people living with HIV. This activity will provide pharmacists with knowledge to better support people living with HIV in initial steps following diagnosis including important aspects of medication selection and monitoring of HIV treatment.
Target audience: Health-system pharmacists, retail pharmacists, and specialty pharmacists
Type of activity: Application
Release date: September 20, 2022
Expiration date: November 20, 2022
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Personalize the onboarding of a treatment-naïve person with HIV
- Explain the differences between drug-resistance testing for antiretrovirals
- Explore medication criteria to consider when choosing antiretroviral therapy in the context of specific comorbid conditions
Linda M. Spooner, PharmD, BCPS, FASHP, FCCP
Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences
School of Pharmacy-Worcester/Manchester
Worcester, Massachusetts
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-392-L02-P. The activity is available for CE credit through November 20, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Linda M. Spooner, PharmD, BCPS, FASHP, FCCP, has the following financial relationships with commercial interests to disclose:
Consultant: Theratechnologies
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms